DK3802517T3 - Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose - Google Patents

Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose Download PDF

Info

Publication number
DK3802517T3
DK3802517T3 DK19731163.2T DK19731163T DK3802517T3 DK 3802517 T3 DK3802517 T3 DK 3802517T3 DK 19731163 T DK19731163 T DK 19731163T DK 3802517 T3 DK3802517 T3 DK 3802517T3
Authority
DK
Denmark
Prior art keywords
fibrosis
treatment
receptor antagonists
alkoxy substituted
substituted pyridinyl
Prior art date
Application number
DK19731163.2T
Other languages
Danish (da)
English (en)
Inventor
Martin Bolli
Christine Brotschi
Cyrille Lescop
Jodi T Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3802517T3 publication Critical patent/DK3802517T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK19731163.2T 2018-06-07 2019-06-05 Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose DK3802517T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07
PCT/EP2019/064690 WO2019234115A1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Publications (1)

Publication Number Publication Date
DK3802517T3 true DK3802517T3 (da) 2023-03-13

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19731163.2T DK3802517T3 (da) 2018-06-07 2019-06-05 Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose

Country Status (22)

Country Link
US (1) US12344597B2 (https=)
EP (1) EP3802517B1 (https=)
JP (1) JP7386183B2 (https=)
KR (1) KR102826034B1 (https=)
CN (1) CN112236424B (https=)
AU (1) AU2019282274A1 (https=)
BR (1) BR112020024879A2 (https=)
CA (1) CA3102683A1 (https=)
DK (1) DK3802517T3 (https=)
EA (1) EA202092955A1 (https=)
ES (1) ES2940695T3 (https=)
FI (1) FI3802517T3 (https=)
HR (1) HRP20230243T1 (https=)
HU (1) HUE061559T2 (https=)
LT (1) LT3802517T (https=)
MX (1) MX2020013291A (https=)
PL (1) PL3802517T3 (https=)
PT (1) PT3802517T (https=)
RS (1) RS63990B1 (https=)
SI (1) SI3802517T1 (https=)
TW (1) TW202016090A (https=)
WO (1) WO2019234115A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (https=) 1960-03-14
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物(3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
EP2212322B1 (en) 2007-10-18 2012-04-04 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
AU2009239500B2 (en) 2008-04-21 2014-01-30 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
PT2303270T (pt) 2008-05-05 2017-08-25 Sanofi Sa Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
KR101678255B1 (ko) * 2009-09-25 2016-11-21 아스텔라스세이야쿠 가부시키가이샤 치환 아미드 화합물
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
DK2648726T3 (da) 2010-12-07 2018-07-16 Amira Pharmaceuticals Inc Polycyklisk lpa1-antagonist og anvendelser deraf
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
PH12013501831B1 (en) 2011-03-10 2019-06-14 Zoetis Services Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
CA2859965A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
EP2970200A1 (en) * 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤

Also Published As

Publication number Publication date
KR102826034B1 (ko) 2025-06-27
MX2020013291A (es) 2021-04-29
JP2021527046A (ja) 2021-10-11
EA202092955A1 (ru) 2021-04-08
LT3802517T (lt) 2023-03-10
PL3802517T3 (pl) 2023-05-22
RS63990B1 (sr) 2023-03-31
EP3802517A1 (en) 2021-04-14
ES2940695T3 (es) 2023-05-10
KR20210018900A (ko) 2021-02-18
PT3802517T (pt) 2023-03-20
TW202016090A (zh) 2020-05-01
SI3802517T1 (sl) 2023-04-28
BR112020024879A2 (pt) 2021-03-09
FI3802517T3 (fi) 2023-03-23
US12344597B2 (en) 2025-07-01
US20210246116A1 (en) 2021-08-12
CA3102683A1 (en) 2019-12-12
CN112236424A (zh) 2021-01-15
CN112236424B (zh) 2024-03-15
HUE061559T2 (hu) 2023-07-28
HRP20230243T1 (hr) 2023-04-14
AU2019282274A1 (en) 2021-01-28
EP3802517B1 (en) 2022-12-21
JP7386183B2 (ja) 2023-11-24
WO2019234115A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
DK3810591T3 (da) Pyridinyl- og pyrazinyl-(aza)indolsulfonamider
DK3621439T3 (da) 4-amino-6-(heterocykliske)picolinater og 6-amino-2-(heterocykliske)pyrimidin-4-carboxylater og deres anvendelse som herbicider
DK3325490T3 (da) 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
DK3802517T3 (da) Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose
IL278546A (en) Activin receptor type iia variants and methods of use thereof
DK3215511T3 (da) Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
IL292692A (en) Mrgprx2 antagonists and uses thereof
DK3429591T3 (da) Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse
DK3288940T3 (da) Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
DK3643713T3 (da) Heterocykliske kinaseinhibitorer og deres anvendelse
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3852748T3 (da) Farnesoid x-receptor-agonister og deres anvendelse
IL251818B (en) Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
DK3319963T3 (da) Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer
EP3868408A4 (en) Antipsychotic and use thereof
IL285025A (en) History of heterocyclic carboxamides, their preparation and use
HUE057569T2 (hu) N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
EP3541378A4 (en) ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE MITIGATION OF PROTEINOPATHIES
ZA202101119B (en) Compounds useful in modulating the farnesoid x receptor and methods of making and using the same
EP3882247A4 (en) SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR
EP3543239C0 (en) SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE